Drug Trial Radar · NCT07768358
Tucatinib Continuation Study
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
175
Planned (sponsor's estimate)
Start
Nov 6, 2026
Primary completion
Mar 13, 2032
Study completion Mar 13, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.
Conditions
- HER2-positive Breast Cancer
- Cervical Cancer
- Biliary Tract Neoplasms
- Urothelial Cancer
- Advanced Non-Small Cell Lung Cancer
- Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
- Colorectal Cancer
Interventions
tucatinibDrug
150 - 300 mg, by mouth, twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- To monitor the safety and tolerability of tucatinibTime frame: Up to approximately 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.